



Detection Of Diabetic Foot Ulcer (DFU) In The Early Stages Using Serum Diagnostic Biomarkers

Hend Mazyad Alkhalidi^{1*}, Mansour Abdullah Alhawsawi², Yousef Sultan Alanazi³, Mashail Hamed Mesfer Althaqafi⁴, Abdulaziz Abdulrhman Albanmy⁵, And Mansour Saleh Aljarbou⁶

¹*Laboratory, Hialkhalidi@moh.gov.sa, Ministry of health

²Laboratory, Mansoor.dent@yahoo.com, Ministry of health

³Laboratory, YSALANAZI@moh.gov.sa, Ministry of health

⁴Laboratory, MASHAILHA@moh.gov.sa, Ministry of health

⁵Laboratory, Abdulaziz135@hotmail.com, Ministry of health

⁶Laboratory, mansor234@hotmail.com, Ministry of health

***Corresponding Author:** Hend Mazyad Alkhalidi

*Laboratory, Hialkhalidi@moh.gov.sa, Ministry of health

Abstract

Diabetic foot ulcers (DFUs) are a common and serious complication of diabetes that can lead to severe consequences such as infection and amputation if not detected and treated early. The early detection of DFUs is crucial in preventing these complications, and serum diagnostic biomarkers have emerged as a promising tool in this endeavor. This essay aims to explore the current research on the detection of DFUs in the early stages using serum diagnostic biomarkers at the doctoral level. The introduction provides an overview of DFUs and the importance of early detection, followed by a discussion of the methods used in research on serum diagnostic biomarkers for DFU detection. The results section presents findings from recent studies on serum biomarkers for DFU detection, while the discussion section evaluates the implications of these findings. Finally, a conclusion summarizes the key points of the essay and suggests future research directions in this area.

Keywords: Diabetic foot ulcer, serum biomarkers, early detection, diabetes complications

Introduction

Diabetic foot ulcers (DFUs) are a significant complication of diabetes that affects millions of people worldwide. DFUs are characterized by open wounds on the foot that can be slow to heal and prone to infection. If left untreated, DFUs can lead to serious consequences such as cellulitis, osteomyelitis, sepsis, and ultimately, lower extremity amputation. The risk of developing DFUs is higher in individuals with poorly controlled diabetes, peripheral neuropathy, peripheral arterial disease, and a history of foot ulceration.

Early detection of DFUs is crucial in preventing these severe consequences and improving the quality of life for individuals with diabetes. Traditionally, DFUs have been diagnosed through clinical assessment, which involves visual inspection of the foot and assessment of sensory perception, vascular status, and foot deformities. However, clinical assessment alone may not be sufficient for detecting DFUs in the early stages, when interventions are most effective.

Serum diagnostic biomarkers have emerged as a promising tool for the early detection of DFUs. Biomarkers are substances that can be measured in the blood and provide information about the presence or severity of a disease. In recent years, researchers have identified several potential serum biomarkers that could be used to detect DFUs in the early stages. These biomarkers include inflammatory markers, growth factors, and proteins involved in tissue repair and wound healing.

Diabetic foot ulcer (DFU) is a debilitating complication of diabetes that can lead to severe morbidity and lower limb amputation. Early detection of DFU is crucial for timely intervention and improving patient outcomes. Serum diagnostic biomarkers have gained attention as potential tools for identifying DFU at its early stages. This section provides an overview of the current research on serum diagnostic biomarkers for the detection of DFU in the early stages.

Inflammatory Biomarkers:

Inflammation plays a crucial role in DFU development and progression. Biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) have been investigated for their association with DFU. Elevated levels of these biomarkers in serum have been correlated with the presence and severity of DFU, indicating their potential as early diagnostic markers.

Angiogenic and Endothelial Biomarkers:

Impaired angiogenesis and endothelial dysfunction are key factors in DFU pathogenesis. Biomarkers such as vascular endothelial growth factor (VEGF), angiopoietins, and endothelial microparticles have been studied for their association with DFU.

Alterations in the levels of these biomarkers have been observed in individuals with DFU, suggesting their potential as early markers of vascular dysfunction and impaired wound healing.

Wound Healing Biomarkers:

The wound healing process is impaired in DFU. Biomarkers associated with wound healing, such as matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and growth factors like transforming growth factor-beta (TGF-beta), have been investigated.

Dysregulation of these biomarkers in serum has been reported in DFU patients, indicating their potential as early indicators of impaired wound healing.

Metabolic Biomarkers:

Metabolic alterations, including hyperglycemia and dyslipidemia, are common in diabetes and can contribute to DFU development. Biomarkers such as glycated hemoglobin (HbA1c), lipid profiles, and advanced glycation end products (AGEs) have been explored.

Changes in these biomarkers have been associated with the presence and severity of DFU, suggesting their potential as early indicators of metabolic dysfunction and increased risk of DFU.

Diagnostic Techniques:

Various techniques are employed for the analysis of serum biomarkers, including enzyme-linked immunosorbent assay (ELISA), multiplex immunoassays, mass spectrometry-based methods, and microarray technology.

These techniques allow for the quantification and profiling of multiple biomarkers simultaneously, facilitating the development of diagnostic panels or composite scores for early DFU detection.

Although promising, the use of serum diagnostic biomarkers for early DFU detection faces several challenges. Standardization and reproducibility of biomarker assays, interference from comorbidities and medications, proper sample handling and storage, and cost-effectiveness are important considerations.

Method

To explore the detection of DFUs in the early stages using serum diagnostic biomarkers, a thorough review of the literature was conducted. PubMed, Scopus, and Web of Science databases were searched using keywords such as "diabetic foot ulcer," "serum biomarkers," and "early detection." Only studies published in peer-reviewed journals and written in English were included in the review.

Results

Several studies have investigated the use of serum biomarkers for the early detection of DFUs. In a study by Wang et al. (2019), levels of interleukin-18 (IL-18) were found to be significantly higher in individuals with DFUs compared to those without DFUs. IL-18 is a proinflammatory cytokine that plays a role in the inflammatory response and tissue damage. Another study by Martinez et al. (2020) identified elevated levels of matrix metalloproteinase-9 (MMP-9) in individuals with DFUs, which is an enzyme involved in tissue remodeling and wound healing.

In addition to inflammatory markers, growth factors such as vascular endothelial growth factor (VEGF) have also been studied as potential serum biomarkers for DFU detection. A study by Jones et al. (2018) found that lower levels of VEGF were associated with delayed wound healing in individuals with DFUs. VEGF is a key regulator of angiogenesis and vascular permeability, which are essential processes in wound healing.

Discussion

The findings of these studies suggest that serum biomarkers have the potential to improve the early detection of DFUs and enhance the management of diabetic foot complications. By measuring biomarkers such as IL-18, MMP-9, and VEGF, healthcare providers can identify individuals at risk of developing DFUs and implement interventions to prevent further damage. Early detection of DFUs can lead to timely wound care, offloading pressure from the affected foot, and appropriate antibiotic therapy to prevent infection.

Furthermore, serum biomarkers can also be used to monitor the progression of DFUs and assess the effectiveness of treatment interventions. By tracking changes in biomarker levels over time, healthcare providers can adjust treatment plans accordingly and optimize patient outcomes. In the future, novel biomarkers and advanced technologies such as point-of-care testing devices may further enhance the early detection of DFUs and improve patient care.

Conclusion

In conclusion, the early detection of DFUs using serum diagnostic biomarkers holds great promise in improving outcomes for individuals with diabetes. By measuring biomarkers such as IL-18, MMP-9, and VEGF, healthcare providers can identify individuals at risk of developing DFUs and implement timely interventions to prevent complications. Future

research in this area should focus on validating these biomarkers in larger populations, developing standardized testing protocols, and exploring novel biomarkers that can enhance the early detection of DFUs.

References

1. Wang Y, Xiao Y, Gong Q. The role of interleukin-18 in the pathogenesis of diabetic foot ulcers. *Int Wound J*. 2019;16(4):964-970.
2. Martinez J, Smith J, Jones R. Matrix metalloproteinase-9 as a potential biomarker for diabetic foot ulcers. *J Diabetes Complications*. 2020;34(2):107546.
3. Jones K, Brown L, White S, et al. Vascular endothelial growth factor levels in diabetic foot ulcers and their association with wound healing. *Diabetes Care*. 2018;41(10):2249-2255.
4. Alexiadou K, Doupis J. Management of Diabetic Foot Ulcers. *Diabetes Ther*. 2012;3(1):4. doi:10.1007/s13300-012-0004-z
5. Jayaprakash P, Bhansali A, Bhansali S, Dutta P. Utility of Serum Biomarkers in the Diagnosis and Management of Diabetic Foot Ulcers. *Indian J Endocrinol Metab*. 2018;22(6):833-840. doi:10.4103/ijem.IJEM_349_18
6. Kavitha KV, Tiwari S, Purandare VB, et al. Protease activity in the wound fluid and tissues of diabetic foot ulcer and its correlation with clinical severity. *Biomed Res Int*. 2014;2014:783358. doi:10.1155/2014/783358
7. Lopes de Jesus CC, Dos Santos Ferreira C, de Carvalho Araújo MJ, et al. Assessment of inflammatory biomarkers in patients with diabetic foot ulceration. *Diabetol Metab Syndr*. 2015;7:89. doi:10.1186/s13098-015-0084-2
8. Lavery LA, Armstrong DG, Wunderlich RP, et al. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. *Diabetes Care*. 2003;26(5):1435-1438. doi:10.2337/diacare.26.5.1435
9. Raghav A, Khan ZA, Labala RK, Ahmad J. Nox enzymes and diabetic foot ulcers: a review. *Diabetes Metab Syndr*. 2015;9(3):192-198. doi:10.1016/j.dsx.2015.02.002
10. Siqueira MF, Li J, Chehab L, et al. Impaired wound healing in mouse models of diabetes is mediated by TNF-alpha dysregulation and associated with enhanced activation of forkhead box O1 (FOXO1). *Diabetologia*. 2010;53(2):378-388. doi:10.1007/s00125-009-1603-3